Horizon Therapeutics plc Announces Phase II Trial Evaluating Dazodalibep for the Treatment of Sjögren’s Syndrome Meets Primary Endpoint in the Second Study Population

The Phase II trial evaluated two patient populations. Dazodalibep is the only medicine in development to achieve the primary endpoint in both patient populations in a Phase II trial.